The funding will support development of a test for the Zika virus using Ontera's silicon nanopore-based molecular diagnostics platform.
A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.
CPIC wants to issue guidelines for non-actionable genes, standardize PGx terms, and work with groups like ClinGen and ClinVar to expand use of its guidelines.
The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.
The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.
The firm said that with the approval, the firm's liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test is now available in every state.
Meeting presentations supported tweaking the clinical interpretation of Genomic Health's Oncotype DX and bolstered Biotheranostics' Breast Cancer Index.
The firm is in the midst of a clinical trial called NOVA to compare its circulating-tumor DNA-based Colvera test to DiaSorin's carcinoembryonic antigen assay.
Harvard and Brigham and Women's Hospital researchers will help guide Sanford in using and interpreting data collected through its Sanford Chip pharmacogenomic test.
The team is now conducting additional studies of mNGS in plasma, as well as looking to reduce turnaround time by running the test on a nanopore sequencer.
Applied BioCode said that it now has access to higher volume laboratories that use the Roche MagNa Pure 96 System for sample extraction.
Last year, the firm saw 21 percent growth in reproductive health, 56 percent growth in oncology, and 49 percent growth in infectious disease testing.
The testing programs are financially supported by the drugmakers, and will allow Invitae to provide free testing and genetic counseling for rare inherited retinal disease and primary immunodeficiencies.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.
The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.
Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement
In almost 1,000 twin pregnancies with known outcomes, cell-free DNA screening of maternal blood correctly classified trisomy 21 cases 94 percent of the time.
Variantyx, a 2014 spinout from Tel Aviv University that is based in Framingham, Massachusetts, provides clinical genomic testing for screening and rare disease diagnostics.
Akonni has received clearance for a molecular diagnostic instrument and a saliva-based pharmacogenomics test for warfarin metabolism.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.
A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.
Broad Institute researchers describe an approach they've dubbed "DNA microscopy."
In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.